公开(公告)号：US20060088600A1

公开(公告)日：2006-04-27

申请号：US10521067

申请日：2003-07-17

申请人： Spencer Thornion ,  Ellen Troyer

发明人： Spencer Thornion ,  Ellen Troyer

IPC分类号： A61K38/16 ,  A61K36/185 ,  A61K31/375 ,  A61K31/202 ,  A61K31/4415

CPC分类号： A61K36/9066 ,  A61K31/07 ,  A61K31/201 ,  A61K31/355 ,  A61K33/06 ,  A61K36/185 ,  A61K38/1709 ,  A61K38/40 ,  A61K2300/00

摘要： A novel formulation for the treatment of the many underlying inflammatory processes that cause dry eye syndrome. In particular, the formulation, which is orally administered includes the optimal blend of omega-3 and omega-6 essential fatty acids, and nutrient cofactors necessary to enhance the metabolic conversion associated with the tear-specific series E-one anti-inflammatory prostaglandin (PGE1). As used herein, the term “nutrient cofactor” refers to a compound that supports and enhances the conversion of linoleic acid to gamma-linolenic acid. Additionally, the formulation inhibits the production of pro-inflammatory compounds, as well as the growth of viral and bacterial pathogens of the three-layer tear film.

摘要翻译： 一种用于治疗导致干眼综合征的许多潜在炎症过程的新型制剂。 特别地，口服给药的制剂包括ω-3和ω-6必需脂肪酸的最佳混合物，以及增强与泪液特异性E系抗炎前列腺素相关的代谢转化所必需的营养辅助因子（ PGE1）。 如本文所用，术语“营养辅助因子”是指支持并增强亚油酸向γ-亚麻酸的转化的化合物。 此外，该制剂抑制促炎化合物的产生，以及三层泪膜的病毒和细菌病原体的生长。

公开(公告)号：US07029712B1

公开(公告)日：2006-04-18

申请号：US10521067

申请日：2003-07-17

申请人： Spencer P. Thornton ,  Ellen Troyer

发明人： Spencer P. Thornton ,  Ellen Troyer

IPC分类号： A61K35/78 ,  A61K35/60 ,  A61K33/06 ,  A61K31/355 ,  A61K31/07

CPC分类号： A61K36/9066 ,  A61K31/07 ,  A61K31/201 ,  A61K31/355 ,  A61K33/06 ,  A61K36/185 ,  A61K38/1709 ,  A61K38/40 ,  A61K2300/00

摘要： A novel formulation for the treatment of the many underlying inflammatory processes that cause dry eye syndrome. In particular, the formulation, which is orally administered includes the optimal blend of omega-3 and omega-6 essential fatty acids, and nutrient cofactors necessary to enhance the metabolic conversion associated with the tear-specific series E-one anti-inflammatory prostaglandin (PGE1). As used herein, the term “nutrient cofactor” refers to a compound that supports and enhances the conversion of linoleic acid to gamma-linolenic acid. Additionally, the formulation inhibits the production of pro-inflammatory compounds, as well as the growth of viral and bacterial pathogens of the three-layer tear film.

摘要翻译： 一种用于治疗导致干眼综合征的许多潜在炎症过程的新型制剂。 特别地，口服给药的制剂包括ω-3和ω-6必需脂肪酸的最佳掺合物，以及增强与泪液特异性E系抗炎前列腺素相关的代谢转化所必需的营养辅助因子（ PGE1）。 如本文所用，术语“营养辅助因子”是指支持并增强亚油酸向γ-亚麻酸的转化的化合物。 此外，该制剂抑制促炎化合物的产生，以及三层泪膜的病毒和细菌病原体的生长。